denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: CSL Behring
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Bleeding disorders, Diseases
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Bleeding disorders, Diseases
Friday, December 6, 2024: 3:00 PM-6:00 PM
Marriott Grand Ballroom 8-9
(Marriott Marquis San Diego Marina)
Speakers:
Steven W. Pipe, MD, University of Michigan
,
Doris V. Quon, MD, PhD, Orthopaedic Hospital
and
Amy Dunn, MD, Nationwide Children's Hospital
Disclosures:
Pipe: Siemens, YewSavin: Research Funding; Scientific Advisory Board GeneVentiv, Equilibra Bioscience: Membership on an entity's Board of Directors or advisory committees; Apcintex, ASC Therapeutics, Bayer, Be Bio, BioMarin, CSL Behring, HEMA Biologics, Freeline, LFB, Metagenomi, Novo Nordisk, Pfizer, Poseida Therapeutics, Precision Bioscience, Regeneron, Roche/Genentech, Sanofi, Takeda, Spark Therapeutics, UniQure: Consultancy. Quon: Pfizer: Honoraria, Other: Consulting /Advisory Boards, Speakers Bureau; Novo Nordisk: Honoraria, Other: Consulting /Advisory Boards, Speakers Bureau; Hemabiologics/LFB: Honoraria, Other: Consulting /Advisory Boards, Speakers Bureau; Genentech/Roche: Honoraria, Other: Consulting /Advisory Boards; CSL Behring: Honoraria, Other: CSL Behring, Speakers Bureau; Sanofi: Honoraria, Other: Consulting /Advisory Boards, Speakers Bureau; Bayer: Honoraria, Other: Consulting /Advisory Boards; Takeda: Honoraria, Other: Consulting /Advisory Boards.
On Demand program will be available here December 21, 2024.
Join us live and in person for an exciting discussion on assessing gene therapies for hemophilia A and hemophilia B. Hematologists, emergency medicine physicians, nurses, nurse practitioners, physician assistants, and other members of the hemophilia care team will benefit from this interactive and nuanced discussion by an expert panel on the clinical and practical evidence surrounding gene therapies for hemophilia, the differences in gene therapies for hemophilia A and hemophilia B, how to identify eligible candidates for gene therapies for hemophilia A and B, monitor patients with hemophilia who receive gene therapies, and how to counsel patients and colleagues about gene therapies for hemophilia A and B.
See more of: Friday Satellite Symposia